Janux Therapeutics, Inc. JANX 深 沪
交易中 09-30 10:17:13 美东时间
23.91
+0.210
+0.89%
华盛通- 最 高23.99
- 今 开23.67
- 成交量 14.53万股
- 最 低 22.915
- 昨 收 23.70
- 总市值 14.15亿
- 52周最高 71.71
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 21.73
- 委 比 -41.62%
- 总股本 5917.52万
- 历史最高 71.71
- 量 比 2.67
- 振 幅 4.54%
- 历史最低 5.65
- 每 手 1
- 风险率 12.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Barclays Initiates Coverage On Janux Therapeutics with Overweight Rating, Announces Price Target of $47
Barclays analyst Etzer Darout initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overweight rating and announces Price Target of $47.
09-17 18:51
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Guggenheim Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $72
Guggenheim analyst Brad Canino initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and announces Price Target of $72.
09-04 22:01
Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
Piper Sandler Initiates Coverage On Janux Therapeutics with Overweight Rating, Announces Price Target of $42
Piper Sandler analyst Kelsey Goodwin initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overweight rating and announces Price Target of $42.
08-19 20:14
Janux Therapeutics Announces The Dosing Of The First Patient In Its TRACTr Collaboration With Merck; First Patient Dosed In The Lead Collaboration Program Triggers A $10M Milestone Payment To Janux
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell
08-06 04:44
Janux Therapeutics Showcases Advancements In TRACTr, TRACIr, And ARM Platforms Ahead Of 2026 Trials At R&D Day Webcast
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses.TROP2-TRACTr adds first-in-class
07-25 04:28
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
07-16 01:35
Raymond James Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $65
Raymond James analyst Sean McCutcheon initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating and announces Price Target of $65.
07-11 21:03
